Close Menu

NEW YORK – Generex Biotechnology, a biopharma and diagnostics firm based in Miramar, Florida, today said that it has signed a letter of intent to acquire immunotherapy firm Kiromic.

Generex said that it intends to merge Kiromic with a newly formed entity, called NuGenerex Immuno-Oncology, that will contain the operations of both Kiromic and Generex subsidiary Antigen Express, which is developing AE37, an experimental cancer vaccine, in combination with checkpoint inhibitors for treatment of triple negative breast cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.


This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.